Kamada Confirms KedRAB Supply Amid Rising U.S. Rabies Demand
REHOVOT, Israel and HOBOKEN, N.J. — September 17, 2026 Kamada Ltd. confirmed that it has sufficient KedRAB® inventory and...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
REHOVOT, Israel and HOBOKEN, N.J. — September 17, 2026 Kamada Ltd. confirmed that it has sufficient KedRAB® inventory and...
SILVER SPRING, Md., June 17, 2026 The U.S. Food and Drug Administration (FDA) has approved the first generic version...
